MA49687A - Anticorps anti-ctla-4 et leurs utilisations - Google Patents

Anticorps anti-ctla-4 et leurs utilisations

Info

Publication number
MA49687A
MA49687A MA049687A MA49687A MA49687A MA 49687 A MA49687 A MA 49687A MA 049687 A MA049687 A MA 049687A MA 49687 A MA49687 A MA 49687A MA 49687 A MA49687 A MA 49687A
Authority
MA
Morocco
Prior art keywords
ctla
antibodies
Prior art date
Application number
MA049687A
Other languages
English (en)
Inventor
Elena Burova
Aynur Hermann
Ella Ioffe
William Olson
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA49687A publication Critical patent/MA49687A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049687A 2017-07-27 2018-07-26 Anticorps anti-ctla-4 et leurs utilisations MA49687A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762537753P 2017-07-27 2017-07-27
US201762588853P 2017-11-20 2017-11-20
US201862645284P 2018-03-20 2018-03-20
US201862685599P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
MA49687A true MA49687A (fr) 2020-06-03

Family

ID=63165545

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049687A MA49687A (fr) 2017-07-27 2018-07-26 Anticorps anti-ctla-4 et leurs utilisations

Country Status (17)

Country Link
US (3) US10844137B2 (fr)
EP (1) EP3658585A1 (fr)
JP (2) JP7296363B2 (fr)
KR (1) KR102710122B1 (fr)
CN (1) CN111133004B (fr)
AU (1) AU2018307675B2 (fr)
BR (1) BR112020001266A2 (fr)
CL (1) CL2020000216A1 (fr)
CO (1) CO2020000438A2 (fr)
IL (1) IL271882B2 (fr)
MA (1) MA49687A (fr)
MY (1) MY202870A (fr)
PH (1) PH12020500078A1 (fr)
SG (1) SG11202000366WA (fr)
TW (1) TWI799432B (fr)
WO (1) WO2019023482A1 (fr)
ZA (1) ZA202000113B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
TWI850282B (zh) 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
EP3898677A1 (fr) 2018-12-21 2021-10-27 OSE Immunotherapeutics Molécule bifonctionnelle anti-pd-1/il -7
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
SG11202109003QA (en) * 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CN113631189A (zh) 2019-03-13 2021-11-09 默沙东公司 包含ctla-4和pd-1封闭剂的抗癌联合治疗
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
CA3162311A1 (fr) * 2019-12-20 2021-06-24 Philip E. Brandish Procedes de traitement d'un cancer a l'aide d'une combinaison d'un antagoniste de pd-1, d'un antagoniste d'ilt4, et d'agents chimiotherapeutiques
JP2023524639A (ja) 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 患者特異的免疫療法用細胞の製造調整システム及び調整方法
AU2021299338A1 (en) * 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
IL299152A (en) * 2020-07-08 2023-02-01 Regeneron Pharma Stabilized formulations that include antibodies against CTLA-4
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
CN116323922A (zh) * 2020-12-17 2023-06-23 南京蓬勃生物科技有限公司 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒
KR20240032711A (ko) 2021-03-25 2024-03-12 이오반스 바이오테라퓨틱스, 인크. T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물
CA3213917A1 (fr) 2021-04-09 2022-10-13 Nicolas Poirier Nouvel echafaudage pour molecules bifonctionnelles presentant des proprietes ameliorees
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
EP4422685A4 (fr) * 2021-10-29 2025-12-03 Oncoc4 Inc Schémas posologiques d'anticorps anti-ctla-4
IL312813A (en) 2021-11-24 2024-07-01 Regeneron Pharma Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
CA3248034A1 (fr) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Procédés d’expansion des cellules til au moyen de combinaisons de cytokines spécifiques et/ou d’un traitement par inhibiteur d’akt
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
KR20250122544A (ko) 2022-11-21 2025-08-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
EP4687990A1 (fr) 2023-03-30 2026-02-11 Ose Immunotherapeutics Procédé de synthèse de nanoparticule lipidique ciblée et ses utilisations
WO2024200823A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation
CN121152808A (zh) * 2023-06-16 2025-12-16 嘉和生物药业有限公司 抗ccr8抗体和抗ccr8/ctla4双特异性抗体
WO2025140478A1 (fr) * 2023-12-29 2025-07-03 百奥泰生物制药股份有限公司 Utilisation d'un anticorps bispécifique anti-pd-l1/cd47 en polythérapie
WO2025242835A1 (fr) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement du cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2112166T3 (en) * 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
EP2240204A1 (fr) * 2008-02-04 2010-10-20 Medarex, Inc. Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
RS59077B1 (sr) * 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2976446A1 (fr) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Agents therapeutiques de type anticorps se liant a ctla4
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
CN107406504B (zh) * 2015-11-19 2021-04-30 蔡则玲 Ctla-4抗体及其用途
WO2018107178A1 (fr) * 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de séquençage de récepteurs de cellules t et leurs utilisations
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途

Also Published As

Publication number Publication date
CN111133004A (zh) 2020-05-08
CL2020000216A1 (es) 2020-07-10
TW201920267A (zh) 2019-06-01
SG11202000366WA (en) 2020-02-27
KR20200032189A (ko) 2020-03-25
IL271882B2 (en) 2025-06-01
EP3658585A1 (fr) 2020-06-03
KR102710122B1 (ko) 2024-09-27
PH12020500078A1 (en) 2020-11-09
US20210040232A1 (en) 2021-02-11
JP2023113893A (ja) 2023-08-16
WO2019023482A1 (fr) 2019-01-31
US10844137B2 (en) 2020-11-24
IL271882A (en) 2020-02-27
AU2018307675A1 (en) 2020-02-20
CA3070790A1 (fr) 2019-01-31
CN111133004B (zh) 2023-12-01
CO2020000438A2 (es) 2020-01-31
ZA202000113B (en) 2021-07-28
US20190048096A1 (en) 2019-02-14
JP2020528750A (ja) 2020-10-01
TWI799432B (zh) 2023-04-21
JP7296363B2 (ja) 2023-06-22
IL271882B1 (en) 2025-02-01
AU2018307675B2 (en) 2024-08-01
BR112020001266A2 (pt) 2020-07-28
US12024570B2 (en) 2024-07-02
MY202870A (en) 2024-05-27
US20250122307A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations